Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epigallocatechin-Gallate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Epigallocatechin-Gallate | EXPERIMENTAL | * Months 1-3: 200 mg EGCG/die (200-0-0 mg) * Months 4-6: 400 mg EGCG/die (200-0-200 mg) * Months 7-9: 600 mg EGCG/die (400-0-200 mg) * Months 10-18: 800 mg EGCG/die (400-0-400 mg) add-on to Donepezil. |
| Placebo | PLACEBO_COMPARATOR | add-on to Donepezil. |
| Name | Type | Description |
|---|---|---|
| Epigallocatechin-Gallate | DRUG | Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg: * Months 1-3: 200 mg EGCG/die (200-0-0 mg) * Months 4-6: 400 mg EGCG/die (200-0-200 mg) * Months 7-9: 600 mg EGCG/die (400-0-200 mg) * Months 10-18: 800 mg EGCG/die (400-0-400 mg) |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * early stage of AD (Diagnosis DSM-IV and NINCDS/ADRDA, Dubois-criteria 2007) * age 60-100 * MMSE 20-26 * patient lives at home with at least one relative who perform external ratings/assessment * co-medication with Donepezil (Aricept®, Pfizer Pharma GmbH) with at least 3 months...
Top 20 of 24 competitors